ArticleOncogene2007
STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 122 citations in OpenAlex.
- B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024Review
- Signal Transducer and Activator of Transcription Proteins at the Nexus of Immunodeficiency, Autoimmunity and Cancer.Biomedicines · 2023Review
- BTB protein family and human breast cancer: signaling pathways and clinical progress.Journal of cancer research and clinical oncology · 2023Review
- B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.Molecular cancer research : MCR · 2022Review
- BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.The Journal of clinical investigation · 2022Article
- Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency.European journal of immunology · 2022Article
- Article
- Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.Cell host & microbe · 2021Article
- STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer.Journal of hematology & oncology · 2021Review
- miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.Blood · 2021Article
- BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.The Journal of clinical investigation · 2021Article
- The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.Frontiers in immunology · 2021Review
- The Timing and Abundance of IL-2Rβ (CD122) Expression Control ThymicFrontiers in immunology · 2021Article
- Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.Oncoimmunology · 2020Article
- Bioinformatic identification and expression analysis of the chicken B cell lymphoma (BCL) gene.Genes & genomics · 2019Article
- Varroa destructor parasitism has a greater effect on proteome changes than the deformed wing virus and activates TGF-β signaling pathways.Scientific reports · 2019Article
- Dysregulation of T Follicular Helper Cells in Lupus.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- Signaling and Function of Interleukin-2 in T Lymphocytes.Annual review of immunology · 2018Review
- STAT5B: A Differential Regulator of the Life and Death of CD4Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.Frontiers in immunology · 2018Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT)5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high inter-species homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.